In my recent article, I discussed Tekmira Pharmaceuticals (TKMR), a biopharmaceutical company focused on RNAi therapeutics. In this article, I will discuss another small cap biotech company Arrowhead Research Corp (NASDAQ:ARWR) which is focused on both RNAi therapeutic and small molecule delivery.
Three Platform Technologies Provide Multiple Applications of Targeted Therapy
Arrowhead Research Corporation is a clinical stage biotech company focused on oncology, obesity, and infectious disease.
Over the years, Arrowhead has developed three proprietary drug delivery platform technologies: Homing Peptides™, Dynamic Polyconjugates (DPCs) ™, and RONDEL™. All three technologies are actively targeted delivery vehicles that can deliver small molecule and siRNA (small interfering RNA) drugs into tissues and cell types of interest while avoiding non-specific
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|